| Chemotherapy regimen(s) | Number in study | Tumour response (partial) | Medial survival (months) | Symptom relief (%) | Comments | Reference |
| Mitomycin, vinblastine, cisplatin (MVP) | 39 (extended study 150) | 20% (extended study 15%) | 6 (extended study 7) | 62 | 110, 111 | |
| Vinorelbine | 29 (extended study 65) | 24% (extended study 21%) | 10.6 (extended study 13) | 50 | 112, 113 | |
| Gemcitabine and cisplatin | 21 | 47.6% | 9.5 | Benefit reported in symptoms | 114 | |
| Other gemcitabine and cisplatin studies | 16–33% | 9.6–13 | 115–117 | |||
| Carboplatin | 26% | 15 | 118 | |||
| Irinotecan, cisplatin, mitomycin | 35% | Response in 30% of patients previously receiving chemotherapy | 119 |